M&As, Medical Innovations, Commercialization, Share Repurchase Programs, and FDA Approvals - Research Report on Life Technologies, Thermo Fisher, Quest Diagnostics, PerkinElmer, and Alere

NEW YORK, August 26, 2013 /PRNewswire/ --

Today, Analysts Corner announced new research reports highlighting Life Technologies Corporation (NASDAQ: LIFE), Thermo Fisher Scientific, Inc. (NYSE: TMO), Quest Diagnostics Inc. (NYSE: DGX), PerkinElmer Inc. (NYSE: PKI), and Alere Inc. (NYSE: ALR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Life Technologies Corporation Research Report

On August 21, 2013, Life Technologies Corporation (Life Technologies) announced that its stockholders have approved the earlier announced merger agreement regarding the acquisition of Life Technologies by Thermo Fisher Scientific. According to the prior announcement by the Company, Thermo Fisher Scientific will acquire Life Technologies for $76.00 per share in cash, subject to potential increase in certain circumstances if the merger does not close by January 14, 2014. Life Technologies further added that the transaction, which is expected to close early in 2014, remains subject to the fulfillment of closing conditions and regulatory approvals. Gregory T. Lucier, Chairman and CEO of Life Technologies, stated, "I want to thank all of our stockholders for their support, which is a testament to the tremendous advantages and opportunities that this transaction provides to stakeholders of both companies. We look forward to joining together with Thermo Fisher in order to accelerate innovation for our customers and achieve greater success in a highly competitive global industry." The Full Research Report on Life Technologies Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/d5de_LIFE]

--

Thermo Fisher Scientific, Inc. Research Report

On August 20, 2013, Thermo Fisher Scientific, Inc. (Thermo Fisher Scientific) announced that its Thermo Scientific ImmunoCAP Peanut Component Tests are now available through Quest Diagnostics. The Company added that Quest Diagnostics is the first national diagnostic information services provider to broadly offer diagnostic services based on the ImmunoCAP tests to physicians, significantly increasing patient access. Thermo Fisher Scientific stated that its non-exclusive agreement with Quest Diagnostics also covers the co-marketing of ImmunoCAP test services provided by Quest Diagnostics' clinical laboratories. The Full Research Report on Thermo Fisher Scientific, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/45ed_TMO]

--

Quest Diagnostics Inc. Research Report

On August 20, 2013, Quest Diagnostics Inc. (Quest Diagnostics) announced that it has increased its share repurchase program by $1 billion to a total authorization of approximately $1.3 billion. Steve Rusckowski, President and CEO of Quest Diagnostics, said, "The increase in our share repurchase authorization is consistent with our long-term disciplined capital deployment strategy, which includes returning the majority of our free cash flow to shareholders." Rusckowski continued, "In addition to our existing capital deployment commitments, we intend to use the approximately $300 million in net proceeds from the recent sale of the ibrutinib royalty rights to repurchase Quest Diagnostics shares as part of our stock buyback program." The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/05ba_DGX]

--

PerkinElmer Inc. Research Report

On August 14, 2013, PerkinElmer Inc. (PerkinElmer) announced the availability of the first early onset preeclampsia screening test in the US. According to the Company, the PreeclampsiaScreen| T1 serum screening test allows physicians to more accurately detect asymptomatic patients in the first trimester of pregnancy who are at a high risk of developing dangerous condition, allowing for earlier identification, management and intervention. Jim Corbett, Senior Vice President and President of Diagnostics and Life Sciences & Technology at PerkinElmer, commented, "This first of its kind screen is our latest commitment to providing clinicians with new, innovative ways to address some of today's most challenging prenatal clinical scenarios. Together with our recent advances, including offering a non-invasive prenatal test based on cell-free fetal DNA, plus a wide range of prenatal testing from biochemical screening to SNP microarray testing to detect birth defects and chromosome abnormalities, we're giving physicians effective new tools for patient management." The Full Research Report on PerkinElmer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/2016_PKI]

--

Alere Inc. Research Report

On August 9, 2013, Alere Inc. (Alere) announced that it has received US Food and Drug Administration (FDA) approval for its pre-market application (PMA) to market Alere Determine HIV 1/2 Ag/Ab Combo in the US for the detection of HIV-1 p24 antigen and antibodies to HIV-1/HIV-2.  According to the Company, the FDA approval allows Alere to market Alere Determine HIV 1/2 Ag/Ab Combo as a Clinical Laboratory Improvement Amendments (CLIA) moderately complex medical device.  Alere informed that Alere Determine™ HIV-1/2 Ag/Ab Combo is the first and only FDA-approved rapid point-of-care test that detects both HIV-1/2 antibodies and the HIV-1 p24 antigen. Avi Pelossof, Global President of Infectious Disease at Alere, said, "We are pleased that the FDA has issued the approval for Alere Determine HIV 1/2 Ag/Ab Combo. Our next step is to complete the CLIA waiver trials with the intention to submit the data in late 2013 or early 2014." The Full Research Report on Whole Foods Market, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/5da1_ALR]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Analysts' Corner